---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-25-000053"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:40:20.809693+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q1 net loss $221.7M; announces $600M Oberland capital deal for troriluzole launch

## Summary
- Net loss of $221.7M ($2.17 per share); non-GAAP adjusted net loss $166.8M ($1.64 per share).
- Cash as of April 30, 2025: ~$518M, after receiving $250M first tranche from Oberland Capital.
- $600M non-dilutive note purchase with Oberland; includes regulatory milestone and royalty on troriluzole sales.
- Troriluzole NDA for SCA under FDA priority review; PDUFA in Q3 2025; mid-cycle review completed without advisory committee.
- Upcoming milestones: pivotal topline data for troriluzole in OCD in 1H 2025, BHV-7000 MDD data in 2H 2025.

## SEC filing metadata
- accession: 0001935979-25-000053
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/0001935979-25-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/bhvn-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-25-000053
- JSON: https://secwatch.observer/filing/0001935979-25-000053.json
- Plain text: https://secwatch.observer/filing/0001935979-25-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.